Company unveils Avantect early cancer detection test portfolio

ClearNote Health™ (formerly known as Bluestar Genomics), a cancer detection company focused on enabling people at risk for high-mortality cancers to live longer healthier lives, today announced that Chief Executive Officer Dave Mullarkey will present a company update at the 41st annual J.P. Morgan Healthcare Conference on Wednesday, January 11 at 2:30 p.m. PST. Mullarkey will discuss the company’s ongoing clinical validation and commercialization efforts across a multi-test portfolio. The Avantect™ early cancer detection portfolio includes the recently launched test for pancreatic cancer, available now for physician ordering in patients over 50 with Type 2 diabetes diagnosed in the past three years.

“Our company made tremendous progress in the last year preparing for commercialization of the Avantect Pancreatic Cancer Test, building an international distribution strategy, and planning for a multi-product portfolio,” said Mullarkey. “This is an inflection point for the company as we turn our attention from validating a single test to developing, validating, and commercializing a suite of cancer detection solutions to address the needs of patients at high risk for cancers with limited screening options and poor outcomes, including pancreatic and ovarian cancers.”

Current trends suggest that pancreatic cancer is poised to become the second leading cause of cancer death within this decade. The Avantect Pancreatic Cancer Test, which received FDA Breakthrough Device designation in 2021, is designed to enable earlier diagnosis for high-risk patients. Launched in 2022, the test combines the most advanced epigenomic hydroxymethylation-based features, and genomic analysis with machine learning to detect the presence or absence of an abnormal pancreatic cancer signal in cell-free DNA from blood.

Following a successful validation study of the Avantect Pancreatic Cancer Test from which data was presented at the American Pancreatic Association meeting in 2022, the company is currently conducting the New Onset Diabetes Management for Earlier Detection (NODMED) trial, one of the largest clinical studies to date in pancreatic cancer. The multisite study is currently enrolling patients recently diagnosed with Type 2 diabetes, a population with eight times the risk of developing pancreatic cancer.

J.P. Morgan Healthcare Conference Presentation Details

Date: January 11, 2023

Time: 2:30 p.m. PST

Location: The Westin St. Francis, Mission Bay Room

To learn more about the Avantect Pancreatic Cancer Test, visit avantect.com.

About ClearNote Health

ClearNote Health is a cancer detection company focused on enabling people at risk for high-mortality cancers to live longer healthier lives. Utilizing a standard blood draw, the company applies its proprietary epigenomic platform, combining biology and artificial intelligence, to identify DNA-based changes in biology as cancer develops. With lead programs in non-invasive early detection of pancreatic and ovarian cancers in patients at the highest risk for these diseases, ClearNote Health identifies cancers before they progress and when patients are most likely to benefit from treatment. ClearNote Health is headquartered in San Diego, with additional presence in the San Francisco Bay area and internationally. The company’s CLIA- and CAP-accredited laboratory is located in San Diego, Calif. For more information, visit www.clearnotehealth.com or follow the company on Twitter or LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230109005189/en/